- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- NATCO PHARMA LIMITED (pharmaceuticals)
- NATCO PHARMA LIMITED Financial Data
Natco Pharma Fact Sheet 
(NTPH)
Here is the latest financial fact sheet of Natco Pharma. For more details, see the Natco Pharma quarterly results and Natco Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.
NATCO PHARMA Price History
| % ch | % | -0.5 |
| No. of shares | m | 166.15 |
| % ch week | % | -9.3 |
| % ch 1-mth | % | -15.1 |
| % ch 12-mth | % | -26.8 |
| 52 week H/L | Rs | 849.0/565.0 |
NATCO PHARMA Financials
| No. of Mths Year Ending |
12 Mar-14* |
12 Mar-15* |
12 Mar-16* |
12 Mar-17* |
12 Mar-18* |
5-Yr Chart Click to enlarge
|
|---|
| NATCO PHARMA EQUITY SHARE DATA | |||||||
|---|---|---|---|---|---|---|---|
| High | Rs | 877 | 2,291 | 624 | 849 | 1,080 | |
| Low | Rs | 424 | 656 | 366 | 418 | 671 | |
| Sales per share (Unadj.) | Rs | 223.4 | 248.4 | 327.8 | 578.9 | 592.1 | |
| Earnings per share (Unadj.) | Rs | 31.1 | 37.6 | 43.5 | 138.9 | 188.4 | |
| Diluted earnings per share | Rs | 6.2 | 7.5 | 9.1 | 29.2 | 41.8 | |
| Cash flow per share (Unadj.) | Rs | 40.3 | 51.8 | 58.2 | 154.5 | 206.3 | |
| Dividends per share (Unadj.) | Rs | 5.00 | 5.00 | 1.25 | 6.75 | 8.25 | |
| Adj. dividends per share | Rs | 1.00 | 1.00 | 0.26 | 1.42 | 1.83 | |
| Dividend yield (eoy) | % | 0.8 | 0.3 | 0.3 | 1.1 | 0.9 | |
| Book value per share (Unadj.) | Rs | 219.5 | 254.6 | 372.8 | 473.8 | 833.6 | |
| Adj. book value per share | Rs | 43.7 | 50.9 | 78.1 | 99.5 | 185.1 | |
| Shares outstanding (eoy) | m | 33.07 | 33.23 | 34.83 | 34.90 | 36.90 | |
| Bonus/Rights/Conversions | PA | - | IS | IS | IS | ||
| Price / Sales ratio | x | 2.9 | 5.9 | 1.5 | 1.1 | 1.5 | |
| Avg P/E ratio | x | 20.9 | 39.2 | 11.4 | 4.6 | 4.6 | |
| P/CF ratio (eoy) | x | 16.1 | 28.4 | 8.5 | 4.1 | 4.2 | |
| Price / Book Value ratio | x | 3.0 | 5.8 | 1.3 | 1.3 | 1.1 | |
| Dividend payout | % | 16.1 | 13.3 | 2.9 | 4.9 | 4.4 | |
| Avg Mkt Cap | Rs m | 21,504 | 48,963 | 17,230 | 22,116 | 32,311 | |
| No. of employees | `000 | NA | 3.1 | 1.3 | 4.4 | 4.8 | |
| Total wages/salary | Rs m | 1,128 | 1,369 | 1,867 | 2,432 | 3,256 | |
| Avg. sales/employee | Rs Th | NM | 2,647.7 | 8,462.6 | 4,579.9 | 4,522.5 | |
| Avg. wages/employee | Rs Th | NM | 439.3 | 1,383.8 | 551.3 | 674.0 | |
| Avg. net profit/employee | Rs Th | NM | 400.8 | 1,124.2 | 1,099.3 | 1,439.0 | |
| NATCO PHARMA INCOME DATA | |||||||
|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 7,389 | 8,253 | 11,416 | 20,202 | 21,848 | |
| Other income | Rs m | 167 | 149 | 108 | 139 | 404 | |
| Total revenues | Rs m | 7,556 | 8,402 | 11,524 | 20,341 | 22,252 | |
| Gross profit | Rs m | 1,793 | 2,100 | 2,640 | 6,834 | 9,284 | |
| Depreciation | Rs m | 304 | 473 | 510 | 544 | 662 | |
| Interest | Rs m | 366 | 317 | 229 | 185 | 154 | |
| Profit before tax | Rs m | 1,290 | 1,459 | 2,009 | 6,244 | 8,872 | |
| Minority Interest | Rs m | 46 | -44 | -14 | 0 | 0 | |
| Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Extraordinary Inc (Exp) | Rs m | 0 | -151 | 0 | 0 | 0 | |
| Tax | Rs m | 309 | 15 | 479 | 1,395 | 1,920 | |
| Profit after tax | Rs m | 1,027 | 1,249 | 1,517 | 4,849 | 6,952 | |
| Gross profit margin | % | 24.3 | 25.4 | 23.1 | 33.8 | 42.5 | |
| Effective tax rate | % | 23.9 | 1.0 | 23.9 | 22.3 | 21.6 | |
| Net profit margin | % | 13.9 | 15.1 | 13.3 | 24.0 | 31.8 | |
| NATCO PHARMA BALANCE SHEET DATA | |||||||
|---|---|---|---|---|---|---|---|
| Current assets | Rs m | 3,681 | 4,830 | 8,323 | 10,873 | 21,307 | |
| Current liabilities | Rs m | 3,123 | 4,137 | 4,929 | 6,265 | 5,920 | |
| Net working cap to sales | % | 7.6 | 8.4 | 29.7 | 22.8 | 70.4 | |
| Current ratio | x | 1.2 | 1.2 | 1.7 | 1.7 | 3.6 | |
| Inventory Days | Days | 89 | 97 | 114 | 63 | 73 | |
| Debtors Days | Days | 59 | 85 | 84 | 86 | 107 | |
| Net fixed assets | Rs m | 7,685 | 8,389 | 9,253 | 11,693 | 14,986 | |
| Share capital | Rs m | 331 | 332 | 348 | 349 | 369 | |
| "Free" reserves | Rs m | 6,670 | 7,945 | 12,373 | 16,144 | 30,353 | |
| Net worth | Rs m | 7,259 | 8,461 | 12,983 | 16,534 | 30,760 | |
| Long term debt | Rs m | 955 | 970 | 0 | 0 | 0 | |
| Total assets | Rs m | 11,957 | 13,840 | 18,238 | 23,176 | 37,151 | |
| Interest coverage | x | 4.5 | 5.6 | 9.8 | 34.8 | 58.6 | |
| Debt to equity ratio | x | 0.1 | 0.1 | 0 | 0 | 0 | |
| Sales to assets ratio | x | 0.6 | 0.6 | 0.6 | 0.9 | 0.6 | |
| Return on assets | % | 11.7 | 11.3 | 9.6 | 21.7 | 19.1 | |
| Return on equity | % | 14.2 | 14.8 | 11.7 | 29.3 | 22.6 | |
| Return on capital | % | 20.7 | 16.8 | 17.1 | 38.9 | 29.3 | |
| Exports to sales | % | 39.4 | 34.7 | 27.5 | 0 | 0 | |
| Imports to sales | % | 5.7 | 6.5 | 10.2 | 0 | 0 | |
| Exports (fob) | Rs m | 2,908 | 2,866 | 3,141 | 0 | 0 | |
| Imports (cif) | Rs m | 421 | 538 | 1,168 | 0 | 0 | |
| Fx inflow | Rs m | 3,445 | 3,156 | 3,457 | 6,793 | 10,322 | |
| Fx outflow | Rs m | 703 | 959 | 1,688 | 2,254 | 2,978 | |
| Net fx | Rs m | 2,743 | 2,197 | 1,769 | 4,538 | 7,343 | |
| NATCO PHARMA CASH FLOW | |||||||
|---|---|---|---|---|---|---|---|
| From Operations | Rs m | 1,440 | 927 | 1,024 | 3,458 | 4,636 | |
| From Investments | Rs m | -1,089 | -1,148 | -1,755 | -2,994 | -11,155 | |
| From Financial Activity | Rs m | -353 | 291 | 856 | -477 | 6,509 | |
| Net Cashflow | Rs m | -1 | 22 | 117 | -7 | -18 | |
Share Holding
|
Company Information
|
|||||||||||||||||||||||||||||||||||||||||
| CHM: V. C. Nannapaneni (MD) | COMP SEC: M. Adinarayana | YEAR OF INC: 1981 | BSE CODE: 524816 | FV (Rs): 10 | DIV YIELD (%): 0.3 |
More Pharmaceuticals Company Fact Sheets: FDC LTD. DISHMAN PHARMA ALEMBIC LTD INDOCO REMEDIES DIVIS LABORATORIES
Compare NATCO PHARMA With: FDC LTD. DISHMAN PHARMA ALEMBIC LTD INDOCO REMEDIES DIVIS LABORATORIES
Compare NATCO PHARMA With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Ends 142 Points Higher; Metal and Healthcare Stocks Witness Buying(Closing)
Indian share markets continued their momentum during closing hours and ended the day on a positive note. Gains were largely seen in the metal sector and healthcare sector.
Views on news
NATCO PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 26.7% (Quarterly Result Update)
Feb 14, 2019 | Updated on Feb 14, 2019For the quarter ended December 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (down 26.7% YoY). Sales on the other hand came in at Rs 6 bn (down 1.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.
NATCO PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 115.2% (Quarterly Result Update)
Nov 12, 2018 | Updated on Nov 12, 2018For the quarter ended September 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 115.2% YoY). Sales on the other hand came in at Rs 5 bn (up 27.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
The Power of 5 Minutes (The 5 Minute Wrapup)
Jun 16, 2017Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
More Views on NewsMost Popular
The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)
Feb 13, 2019The real estate sector is ready to make a comeback. This is the stock to consider buying.
Don't Be Afraid of the Market; Buy Stocks Like This One(The 5 Minute Wrapup)
Feb 14, 2019During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.
How We Pick the Most Profitable Stocks from the Portfolios of Super Investors(The 5 Minute Wrapup)
Feb 8, 2019This is the trick to following super investors and not losing money.
Small Caps Under Seige: Could This Be A Once-in-a-Decade Wealth Creating Opportunity?(Profit Hunter)
Feb 14, 2019Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.
The Train to 'Small-Cap-Profits Land' is Back on the Station!(Profit Hunter)
Feb 15, 2019Why its great news that prices for small caps over the last few days have been falling like there's no tomorrow.
More|
| |
TRACK NATCO PHARMA
- Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON NATCO PHARMA
NATCO PHARMA - MYLAN COMPARISON
COMPARE NATCO PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.